세계의 음성 기분 장애 Dx 시장 예측 : 구성요소별, 전개 모드별, 질환 유형별, 바이오마커 유형별, 기술별, 용도별, 최종 사용자별, 지역별 분석(-2032년)

According to Stratistics MRC, the Global Voice Mood Disorder Dx Market is accounted for $599.92 million in 2025 and is expected to reach $1519.68 million by 2032 growing at a CAGR of 14.2% during the forecast period. The Voice Mood Disorder Dx describes the growing application of AI-driven analysis and voice-based biomarkers for the diagnosis and tracking of mood disorders like bipolar disorder, anxiety, and depression. Tone, pitch, rhythm, intensity, and pauses are just a few examples of the subtle changes in speech patterns that frequently reveal underlying emotional and cognitive states that are difficult to identify with conventional clinical evaluations. By analyzing these characteristics using natural language processing (NLP) and machine learning, Voice Mood Disorder Dx systems provide a non-invasive, scalable, and real-time mental health assessment. Early detection, ongoing monitoring, and integration with telehealth platforms are all possible with this technology, which could enhance patient accessibility and individualized treatment plans.

According to a study published in Frontiers in Neurology, voice-based machine learning models have demonstrated the ability to diagnose depressive and manic mood states by analyzing 1,337 voice messages from 93 participants. The study found that specific vocal features, such as pitch, rhythm, and pauses, were indicative of mood states, suggesting the potential of voice analysis in mood disorder diagnostics.

Market Dynamics:

Driver:

Increasing mental health disorder prevalence

The prevalence of mental health issues is raising quickly throughout the world, especially mood disorders like bipolar disorder, anxiety, and depression. Women are disproportionately affected by depression, which affects over 280 million people globally, according to the World Health Organization. Accurate diagnosis and intervention may be delayed by the use of subjective evaluations and self-reports in traditional diagnostic techniques. There is an immediate need for novel, trustworthy, and scalable diagnostic tools as a result of this increasing prevalence. Moreover, a promising approach to early detection, ongoing monitoring, and better management of mental health disorders worldwide is voice-based diagnostics, which examine minute vocal changes linked to emotional states.

Restraint:

Data security and privacy issues

Voice-based diagnostics present serious privacy issues since they necessitate the gathering and examination of private health and personal information. Patients may be concerned that their vocal and emotional data may be misused, accessed without authorization, or compromised. Although regulatory frameworks such as GDPR in Europe and HIPAA in the United States enforce stringent compliance standards, regional variations pose difficulties for global implementation. Providing voice data with secure storage, encrypted transmission, and appropriate anonymization is expensive and technically challenging. Furthermore, adoption may be slowed by public mistrust of digital health platforms. Rapid market expansion may be limited if companies are unable to maintain patient trust and comply with legal requirements while balancing innovation with strict data protection measures.

Opportunity:

Extension of remote monitoring and telehealth

The quick development of telehealth offers a big chance for voice-based diagnosis of mood disorders. Integrating voice analysis tools into telemedicine platforms can enable ongoing mental health monitoring without requiring in-person visits, as patients increasingly seek out remote consultations. Clinicians can use remote monitoring to monitor subtle behavioral and emotional changes over time, allowing for early intervention and individualized treatment plans. Additionally, by lowering barriers for patients in underserved or rural areas, this integration broadens the market. The COVID-19 pandemic and other events have accelerated the demand for digital health solutions. As a result, telehealth adoption offers a favorable environment for the global deployment of scalable, voice-based mental health diagnostics.

Threat:

Strong rivalry and quick changes in technology

The market is getting more and more competitive, with established tech firms, startups, and providers of healthcare solutions fighting for market share. If current tools do not adapt to the rapid advancements in technology, they may soon become outdated. Competitors may gain market share by providing more precise, affordable, or user-friendly solutions, which would put pressure on margins and impede growth. Although it raises operating costs and risk, ongoing R&D investment is necessary to remain relevant. Due to the rapid advancement of AI, natural language processing, and digital health technologies, businesses must constantly adjust or risk falling behind more sophisticated diagnostic tools.

Covid-19 Impact:

The Voice Mood Disorder Dx market was significantly impacted by the COVID-19 pandemic, which presented both opportunities and difficulties. Globally, mental health problems increased as a result of social isolation, lockdowns, and elevated stress levels, which raised the need for early mood disorder detection and monitoring. Social distancing policies made it more difficult to conduct traditional in-person evaluations, which sped up the use of non-invasive, remote diagnostic tools like voice-based ones. AI-powered voice analysis was incorporated into telehealth platforms to facilitate early intervention, ongoing monitoring, and individualized treatment. However, the abrupt change also brought to light issues with digital literacy, infrastructure, and data privacy that businesses needed to resolve in order to continue growing.

The cloud segment is expected to be the largest during the forecast period

The cloud segment is expected to account for the largest market share during the forecast period because of their scalability, flexibility, and cheaper infrastructure costs than on-premise deployments, cloud-based solutions are recommended. Without requiring a lot of hardware at the user's location, they make it possible to collect, process, and analyze voice biomarker data in real time. Cloud platforms facilitate machine learning models and AI-driven analytics, enabling remote access and ongoing monitoring for both patients and clinicians. Furthermore, cloud solutions improve accessibility and adoption by enabling smooth integration with mobile apps and telehealth services. Centralized algorithm updates also guarantee more precise, current diagnostic capabilities, which propel the segment's market leadership.

The telehealth providers segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the telehealth providers segment is predicted to witness the highest growth rate. The need for telehealth platforms that can provide voice-based mood and mental health assessments has increased dramatically due to the growing use of remote healthcare solutions, particularly in the wake of COVID-19. These providers close gaps in mental health care, especially in underserved areas, by allowing patients to obtain diagnostic services from the convenience of their homes. Moreover, the fastest-growing market segment is telehealth due to developments in AI-driven voice analysis tools that enable real-time, precise mood detection, improving early intervention and individualized treatment.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by the region's substantial investment in mental health research, high adoption of digital health technologies, and sophisticated healthcare infrastructure. Leading healthcare providers, diagnostic firms, and encouraging regulatory environments all contribute to the market's expansion. Widespread adoption has also been aided by growing knowledge of mental health issues and the use of voice-based and AI-based diagnostic tools in clinical settings. Additionally, North America's leadership in the global voice mood disorder diagnostics market is cemented by robust government initiatives and the rising demand for remote and customized diagnostic solutions.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. Digital diagnostic solutions are being adopted in nations like China, India, and Japan due to factors like rapid urbanization, rising internet and smartphone penetration, and increased awareness of mental health issues. The incorporation of AI-based voice analysis tools for the early detection of mood disorders and increased investments in healthcare infrastructure are also driving market expansion. Furthermore, Asia-Pacific is emerging as the region with the fastest rate of growth in the global voice mood disorder diagnostics market thanks to supportive government initiatives, the growth of telehealth, and the development of mobile health platforms.

Key players in the market

Some of the key players in Voice Mood Disorder Dx Market include Cogito Corporation, Sonde Health, Ellipsis Health Inc, Psyrin, Canary Speech Inc, Beyond Verbal, Thymia, Kintsugi, CompanionMx, LangAware, Vocalis Health, Winterlight Labs, Mindstrong Health, NeuroLex Laboratories and Aiberry Inc.

Key Developments:

In June 2025, Ellipsis Health announced it has raised $45 million in a new Series A funding round. Salesforce, Khosla Ventures and CVS Health Ventures led the round. Mitsui Global Investment, Collier, E12 and AME Cloud Ventures participated in the round. The company is also introducing Sage, an AI care manager aimed at supporting patients with physical, behavioral and social needs.

In August 2024, Sonde Health announces it has been selected by AFWERX for a SBIR Phase II contract in the amount of $1,215,606 focused on Sonde Mental Fitness to address the most pressing challenges in the Department of the Air Force (DAF).

In October 2023, Cogito announced it has secured new funding to help advance features aimed at better supporting agents in the contact center and improving customer experiences. The funding round, including repeat commitments from two major investors, validates the importance of delivering strong employee and customer experiences in today's turbulent economic climate.

Components Covered:

• Solutions
• Services

Deployment Modes Covered:

• Cloud
• On-premise

Disorder Types Covered:

• Depression
• Bipolar Disorder
• Anxiety Disorders
• Post-Traumatic Stress Disorder (PTSD)
• Schizophrenia
• Other Disorder Types

Biomarker Types Covered:

• Frequency-based Biomarkers
• Amplitude-based Biomarkers
• Vocal Fold Dynamics-based Biomarkers
• Other Biomarker Types

Technologies Covered:

• Voice Biomarkers
• Natural Language Processing (NLP)
• Machine Learning Algorithms
• Acoustic Signal Processing

Applications Covered:

• Cognitive
• Behavioral

End Users Covered:

• Hospitals & Clinics
• Diagnostic Centers
• Telehealth Providers
• Research Institutions
• Mental Health Apps & Platforms

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Technology Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Voice Mood Disorder Dx Market, By Component

• 5.1 Introduction
• 5.2 Solutions
• 5.3 Services

6 Global Voice Mood Disorder Dx Market, By Deployment Mode

• 6.1 Introduction
• 6.2 Cloud
• 6.3 On-premise

7 Global Voice Mood Disorder Dx Market, By Disorder Type

• 7.1 Introduction
• 7.2 Depression
• 7.3 Bipolar Disorder
• 7.4 Anxiety Disorders
• 7.5 Post-Traumatic Stress Disorder (PTSD)
• 7.6 Schizophrenia
• 7.7 Other Disorder Types

8 Global Voice Mood Disorder Dx Market, By Biomarker Type

• 8.1 Introduction
• 8.2 Frequency-based Biomarkers
• 8.3 Amplitude-based Biomarkers
• 8.4 Vocal Fold Dynamics-based Biomarkers
• 8.5 Other Biomarker Types

9 Global Voice Mood Disorder Dx Market, By Technology

• 9.1 Introduction
• 9.2 Voice Biomarkers
• 9.3 Natural Language Processing (NLP)
• 9.4 Machine Learning Algorithms
• 9.5 Acoustic Signal Processing

10 Global Voice Mood Disorder Dx Market, By Application

• 10.1 Introduction
• 10.2 Cognitive
• 10.3 Behavioral

11 Global Voice Mood Disorder Dx Market, By End User

• 11.1 Introduction
• 11.2 Hospitals & Clinics
• 11.3 Diagnostic Centers
• 11.4 Telehealth Providers
• 11.5 Research Institutions
• 11.6 Mental Health Apps & Platforms

12 Global Voice Mood Disorder Dx Market, By Geography

• 12.1 Introduction
• 12.2 North America
  • 12.2.1 US
  • 12.2.2 Canada
  • 12.2.3 Mexico
• 12.3 Europe
  • 12.3.1 Germany
  • 12.3.2 UK
  • 12.3.3 Italy
  • 12.3.4 France
  • 12.3.5 Spain
  • 12.3.6 Rest of Europe
• 12.4 Asia Pacific
  • 12.4.1 Japan
  • 12.4.2 China
  • 12.4.3 India
  • 12.4.4 Australia
  • 12.4.5 New Zealand
  • 12.4.6 South Korea
  • 12.4.7 Rest of Asia Pacific
• 12.5 South America
  • 12.5.1 Argentina
  • 12.5.2 Brazil
  • 12.5.3 Chile
  • 12.5.4 Rest of South America
• 12.6 Middle East & Africa
  • 12.6.1 Saudi Arabia
  • 12.6.2 UAE
  • 12.6.3 Qatar
  • 12.6.4 South Africa
  • 12.6.5 Rest of Middle East & Africa

13 Key Developments

• 13.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 13.2 Acquisitions & Mergers
• 13.3 New Product Launch
• 13.4 Expansions
• 13.5 Other Key Strategies

14 Company Profiling

• 14.1 Cogito Corporation
• 14.2 Sonde Health
• 14.3 Ellipsis Health Inc
• 14.4 Psyrin
• 14.5 Canary Speech Inc
• 14.6 Beyond Verbal
• 14.7 Thymia
• 14.8 Kintsugi
• 14.9 CompanionMx
• 14.10 LangAware
• 14.11 Vocalis Health
• 14.12 Winterlight Labs
• 14.13 Mindstrong Health
• 14.14 NeuroLex Laboratories
• 14.15 Aiberry Inc